Taken together, these results provide evidence that GMPR1 can be a therapeutic target and that lumacaftor has therapeutic effects on AD, especially in preventing the accumulation of Aβ and eliminating Tau phosphorylation. Here, MAPT is linked to Alzheimer disease.